Combination of curcumin and gemcitabine suppresses tumor progression and decreases the level of LAT2, CK19 and HMGB1 in a gemcitabine-resistant CCA xenograft mouse model and in a hamster CCA model. This evidence concerns the gene HMGB1 and neoplasm.